ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

Kemas kini terakhir: 3 hari lalu, 6:52AM

230.11

-2.24 (-0.96%)

  • 1H -0.96%
  • 5H -0.85%
  • 1B 4.17%
  • 6B 4.49%
  • Tahun Ke Tarikh 0.35%
  • 1T 7.73%
  • 5T 113.32%
Penutupan Terdahulu 232.35
Buka 230.36
Jumlah Dagangan 4,460,535
Purata Dagangan (3B) 6,732,291
Modal Pasaran 406,873,374,720
Harga / Pendapatan (P/E TTM) 97.09
Harga / Pendapatan (P/E Ke hadapan) 16.84
Harga / Jualan (P/S) 7.19
Harga / Buku (P/B) 50.46
Julat 52 Minggu
164.39 (-28%) — 244.81 (6%)
Tarikh Pendapatan 1 May 2026
Hasil Dividen (DY TTM) 0.71%
Margin Keuntungan 7.31%
Margin Operasi (TTM) 30.43%
EPS Cair (TTM) 2.35
Pertumbuhan Hasil Suku Tahunan (YOY) 8.40%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -6.10%
Jumlah Hutang/Ekuiti (D/E MRQ) 4,789.60%
Nisbah Semasa (MRQ) 0.760
Aliran Tunai Operasi (OCF TTM) 16.40 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 16.94 B
Pulangan Atas Aset (ROA TTM) 8.34%
Pulangan Atas Ekuiti (ROE TTM) 88.40%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Bercampur
Drug Manufacturers - General (Global) Menaik Bercampur
Stok AbbVie Inc. Menaik Menaik

AISkor Stockmoo

0.4
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam -3.0
Volatiliti Harga -0.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal 4.0
Purata 0.40

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ABBV 407 B 0.71% 97.09 50.46
JNJ 586 B 2.14% 22.01 7.20
MRK 306 B 0.65% 17.01 5.65
PFE 155 B 6.20% 20.07 1.76
BMY 124 B 4.84% 17.53 6.74
GSK 109 B 1.62% 14.69 5.29

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.10%
% Dimiliki oleh Institusi 74.87%
Julat 52 Minggu
164.39 (-28%) — 244.81 (6%)
Julat Harga Sasaran
228.00 (-0%) — 299.00 (29%)
Tinggi 299.00 (Piper Sandler, 29.94%) Beli
Median 260.00 (12.99%)
Rendah 228.00 (Evercore ISI Group, -0.92%) Beli
Purata 256.00 (11.25%)
Jumlah 5 Beli, 2 Pegang
Harga Purata @ Panggilan 223.06
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
RBC Capital 25 Feb 2026 260.00 (12.99%) Beli 226.92
Barclays 20 Feb 2026 275.00 (19.51%) Beli 224.81
Piper Sandler 18 Feb 2026 299.00 (29.94%) Beli 228.72
Evercore ISI Group 05 Feb 2026 228.00 (-0.92%) Beli 219.02
Morgan Stanley 05 Feb 2026 270.00 (17.34%) Beli 219.02
12 Dec 2025 269.00 (16.90%) Beli 223.32
UBS 05 Feb 2026 230.00 (-0.05%) Pegang 219.02
07 Jan 2026 240.00 (4.30%) Pegang 233.42
Citigroup 27 Jan 2026 230.00 (-0.05%) Pegang 223.93
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
SIATIS PERRY C - 226.92 -22,381 -5,078,697
Jumlah Keseluruhan Kuantiti Bersih -22,381
Jumlah Keseluruhan Nilai Bersih ($) -5,078,697
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) 226.92
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
SIATIS PERRY C Pegawai 25 Feb 2026 Jual (-) 22,381 226.92 5,078,697
SIATIS PERRY C Pegawai 25 Feb 2026 Pelaksanaan pilihan 22,381 - -
  • 3M
Tarikh Jenis Butiran
04 Feb 2026 Pengumuman AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
03 Feb 2026 Pengumuman Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
03 Feb 2026 Pengumuman AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
30 Jan 2026 Pengumuman $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
29 Jan 2026 Pengumuman AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
28 Jan 2026 Pengumuman Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
16 Jan 2026 Pengumuman AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
12 Jan 2026 Pengumuman AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
12 Jan 2026 Pengumuman AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
12 Jan 2026 Pengumuman West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
12 Jan 2026 Pengumuman AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
07 Jan 2026 Pengumuman AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
05 Jan 2026 Pengumuman AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
19 Dec 2025 CNBC Nine of the largest pharma companies ink deals with Trump to lower drug prices
14 Dec 2025 TheFinance 3 US Dividend Stocks Every Singapore Investor Should Know
Papar semua
Hasil Dividen (DY TTM) 0.71%
Purata Hasil Dividen 5T 3.22%
Nisbah Pembayaran 268.80%
Jangkaan Pembayaran Dividen Seterusnya May 2026
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
15 Apr 2025 13 Feb 2025 15 May 2025 1.64 Tunai
15 Jan 2025 30 Oct 2024 14 Feb 2025 1.64 Tunai
15 Oct 2024 06 Sep 2024 15 Nov 2024 1.55 Tunai
15 Jul 2024 20 Jun 2024 15 Aug 2024 1.55 Tunai
12 Apr 2024 15 Feb 2024 15 May 2024 1.55 Tunai
12 Jan 2024 27 Oct 2023 15 Feb 2024 1.55 Tunai
12 Oct 2023 08 Sep 2023 15 Nov 2023 1.48 Tunai
13 Jul 2023 22 Jun 2023 15 Aug 2023 1.48 Tunai
13 Apr 2023 16 Feb 2023 15 May 2023 1.48 Tunai
12 Jan 2023 28 Oct 2022 15 Feb 2023 1.48 Tunai
13 Oct 2022 09 Sep 2022 15 Nov 2022 1.41 Tunai
14 Jul 2022 23 Jun 2022 15 Aug 2022 1.41 Tunai
13 Apr 2022 17 Feb 2022 16 May 2022 1.41 Tunai
13 Jan 2022 29 Oct 2021 15 Feb 2022 1.41 Tunai
14 Oct 2021 10 Sep 2021 15 Nov 2021 1.3 Tunai
14 Jul 2021 17 Jun 2021 16 Aug 2021 1.3 Tunai
14 Apr 2021 18 Feb 2021 14 May 2021 1.3 Tunai
14 Jan 2021 30 Oct 2020 16 Feb 2021 1.3 Tunai
14 Oct 2020 11 Sep 2020 16 Nov 2020 1.18 Tunai
14 Jul 2020 17 Jun 2020 14 Aug 2020 1.18 Tunai
14 Apr 2020 20 Feb 2020 15 May 2020 1.18 Tunai
14 Jan 2020 01 Nov 2019 14 Feb 2020 1.18 Tunai
11 Oct 2019 06 Sep 2019 15 Nov 2019 1.07 Tunai
12 Jul 2019 21 Jun 2019 15 Aug 2019 1.07 Tunai
12 Apr 2019 22 Feb 2019 15 May 2019 1.07 Tunai
14 Jan 2019 02 Nov 2018 15 Feb 2019 1.07 Tunai
12 Oct 2018 08 Sep 2018 15 Nov 2018 0.96 Tunai
12 Jul 2018 15 Jun 2018 15 Aug 2018 0.96 Tunai
12 Apr 2018 15 Feb 2018 15 May 2018 0.96 Tunai
11 Jan 2018 27 Oct 2017 15 Feb 2018 0.71 Tunai
12 Oct 2017 08 Sep 2017 15 Nov 2017 0.64 Tunai
12 Jul 2017 22 Jun 2017 15 Aug 2017 0.64 Tunai
11 Apr 2017 16 Feb 2017 15 May 2017 0.64 Tunai
11 Jan 2017 28 Oct 2016 15 Feb 2017 0.64 Tunai
12 Oct 2016 09 Sep 2016 15 Nov 2016 0.57 Tunai
13 Jul 2016 16 Jun 2016 15 Aug 2016 0.57 Tunai
13 Apr 2016 18 Feb 2016 16 May 2016 0.57 Tunai
13 Jan 2016 30 Oct 2015 16 Feb 2016 0.57 Tunai
13 Oct 2015 11 Sep 2015 16 Nov 2015 0.51 Tunai
13 Jul 2015 18 Jun 2015 14 Aug 2015 0.51 Tunai
13 Apr 2015 19 Feb 2015 15 May 2015 0.51 Tunai
13 Jan 2015 20 Oct 2014 13 Feb 2015 0.49 Tunai
10 Oct 2014 19 Sep 2014 17 Nov 2014 0.42 Tunai
11 Jul 2014 19 Jun 2014 15 Aug 2014 0.42 Tunai
11 Apr 2014 20 Feb 2014 15 May 2014 0.42 Tunai
13 Jan 2014 12 Dec 2013 14 Feb 2014 0.4 Tunai
10 Oct 2013 19 Sep 2013 15 Nov 2013 0.4 Tunai
11 Jul 2013 20 Jun 2013 15 Aug 2013 0.4 Tunai
11 Apr 2013 15 Feb 2013 15 May 2013 0.4 Tunai
11 Jan 2013 04 Jan 2013 15 Feb 2013 0.4 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 3.28 2 1.44
2024 6.20 4 3.49
2023 5.92 4 3.82
2022 5.64 4 3.49
2021 5.20 4 3.84
2020 4.72 4 4.41
2019 4.28 4 4.83
2018 3.59 4 3.89
2017 2.56 4 2.65
2016 2.28 4 3.64
2015 2.02 4 3.41
2014 1.66 4 2.54
2013 1.60 4 3.03
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda